• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Ocular Therapeutix (OCUL)

Common Shares
Sell: $11.15|Buy: $11.20|Change: 0.18 (-1.99%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Address

24 Crosby Drive
Bedford
MA
USA
01730

Telephone

+1 877 6288998

Website

https://www.ocutx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Ocular Therapeutix Inc Fourth Quarter Earnings Results for 20262027-02-05T00:00:00
Ocular Therapeutix Inc Third Quarter Earnings Conference Call for 20262026-11-04T08:00:00
Ocular Therapeutix Inc Third Quarter Earnings Results for 20262026-11-04T00:00:00
Ocular Therapeutix Inc Second Quarter Earnings Conference Call for 20262026-08-05T08:00:00
Ocular Therapeutix Inc Second Quarter Earnings Results for 20262026-08-05T00:00:00
Ocular Therapeutix Inc Annual General Meeting for 20262026-06-11T08:30:00
Ocular Therapeutix Inc First Quarter Earnings Results for 20262026-05-05T07:00:00
Ocular Therapeutix Inc Annual Report for 20252026-03-03T00:00:00
Ocular Therapeutix SOL-1 Topline Data Call 20262026-02-17T08:00:00
Ocular Therapeutix Inc Fourth Quarter Earnings Results for 20252026-02-05T00:00:00

Previous key dates

NameKey Date
Ocular Therapeutix SOL-1 Topline Data Call 20262026-02-17T08:00:00
Ocular Therapeutix Inc Fourth Quarter Earnings Results for 20252026-02-05T00:00:00
Piper Sandler 37th Annual Healthcare Conference2025-12-03T08:30:00
Jefferies Global Healthcare Conference2025-11-18T14:30:00
Ocular Therapeutix Inc Third Quarter Earnings Conference Call for 20252025-11-04T08:00:00
Ocular Therapeutix Inc Third Quarter Earnings Result for 20252025-11-04T00:00:00
Investor Day 20252025-09-30T14:00:00
Ocular Therapeutix, Inc. Baird 2025 Global Healthcare Conference2025-09-09T12:50:00
Ocular Therapeutix, Inc. Morgan Stanley 23rd Annual Global Healthcare Conference 20252025-09-08T14:35:00
Ocular Therapeutix Inc Second Quarter Earnings Conference Call for 20252025-08-05T08:00:00
Ocular Therapeutix Inc Second Quarter Earnings Result for 20252025-08-05T00:00:00
Ocular Therapeutix Inc Annual General Meeting for 20252025-06-11T08:30:00
Bank of America 2025 Global Healthcare Conference2025-05-13T09:00:00
Citizens JMP Life Sciences Conference 20252025-05-07T09:00:00
Ocular Therapeutix Inc First Quarter Earnings Results for 20252025-05-05T07:00:00
24th Annual Needham Virtual Healthcare Conference2025-04-07T15:00:00
Leerink Partners Global Healthcare Conference 20252025-03-10T10:00:00
TD Cowen 45th Annual Health Care Conference2025-03-04T11:50:00
Ocular Therapeutix Inc Fourth Quarter Earnings Conference Call for 20242025-03-03T08:00:00
Ocular Therapeutix Inc Fourth Quarter Earnings Result for 20242025-03-03T00:00:00
Ocular Therapeutix Inc Annual Report for 20242025-03-03T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.